Krishnan Suma sold $7.7M of KRYS

Krystal Biotech (NASDAQ:KRYS) reported that its investigational immunotherapy KB113 showed regression in 83% of assessed basal cell carcinoma lesions in a pilot study of three Gorlin syndrome patients. The company has begun FDA discussions for further development. Biopsies confirmed complete responses in three lesions. The study is small and preliminary, with larger trials needed to confirm efficacy and safety.

Krystal Biotech reported that KB113 showed over 80% lesion regression in a three-patient Gorlin syndrome pilot study, with both injected and non-injected lesions regressing. The treatment was well tolerated, with mild/moderate adverse events. The company is discussing advanced clinical development plans with the FDA.

Krystal Biotech, Inc. (KRYS) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 Krystal Biotech Announces Positive Clinical Data for New Dermatology Program KB113 Demonstrating Broad Basal Cell Carcinoma Regression in Patients with Gorlin Syndrome Over 80% of assessed basal cell carcinoma lesions regressed across three Gorlin syndrome patients t

Eli Lilly (LLY) reported Q2 results that beat forecasts and raised 2026 GAAP revenue guidance to $85B-$87B. Q2 revenue rose 48% to $22.974B and net income rose 25% to $7.095B. Leerink raised its 12-month price target to $1,309. Krystal Biotech (KRYS) shares fell after a slight Vyjuvek revenue miss, though analysts cited strong patient growth.

Krystal Biotech (KB) shares fell more than 10% after Q2 results. The company reported $119.2M global net product revenue from VYJUVEK, up 24% year over year, with cumulative revenue of $965.9M and 95% gross margin. Net income was $54.8M ($1.85 basic EPS). Cash totaled $1.1B. Investors focused on U.S. uptake and international reimbursement timing.

Krystal Biotech (KRYS) shares fell about 6% in pre-open after it reported Q2 2026 results. The company posted $119.2M in global VYJUVEK net revenue, up 24% year over year but below analyst consensus near $126M. Gross margin was 95% and prescribers rose above 640, but the revenue miss drove selling.